80 results about "Enteric coating" patented technology

The invention discloses a non-invasive intestinal flora fixed-point sampling and drug release device, and belongs to the technical field of micro-ecological diagnosis and treatment. The device comprises a shell, an internal storage bin, a medicine loading cavity and a channel switching mechanism. The shell adopts a capsule-shaped design, and an enteric coating is arranged on the surface of the shell, so that the function is started after the shell reaches a specified position of an intestinal tract. Through the internal ingenious mechanism linkage design, the device can firstly complete non-invasive fixed-point sampling of intestinal contents, and after the sampling action is completed, a drug release mechanism is automatically triggered, so that accurate drug delivery of the same part is realized. Cooperative operation of sampling and drug release in time sequence and space is achieved, and the problems of pain, disjunction of the diagnosis and treatment process, poor drug targeting and the like caused by traditional invasive operation are effectively solved. The device is flexible in structural design, has the advantages of being noninvasive, efficient, accurate in time sequence control and the like, and is suitable for integrated application of diagnosis and treatment of various digestive tract diseases such as inflammatory bowel disease management, micro-ecological regulation and the like.

The invention provides an oral solid formulation comprising (a) a plurality of controlled release components comprising (i) a core comprising a mixture of levodopa and at least one pharmaceutically acceptable excipient, (ii) a controlled release coating surrounding the core, (iii) a muco-adhesive coating surrounding the controlled release coating and (iv) an enteric coating surrounding the muco-adhesive coating; and (b) one or more immediate release components comprising levodopa. The oral solid formulation also contains carbidopa and about 80% to 100% of the carbidopa in the oral solid formulation is present in the one or more immediate release components.

This invention discloses a multi-target synergistic anti-liver cancer medical food granule and its preparation method. The granule uses medicinal and edible homologous foods and novel resource foods as raw materials, and is composed of curcumin extract, esterified fat-soluble EGCG, Moringa leaf powder, yeast β-glucan, Astragalus extract, Schisandra extract, Salvia miltiorrhiza extract, Poria cocos powder, resistant dextrin, and erythritol in a specific ratio to construct a three-dimensional synergistic system of "direct killing-immune regulation-liver protection," which can induce ferroptosis in liver cancer cells, inhibit protective autophagy, activate the body's immunity, and protect liver cells. This invention employs directional extraction, multi-layer coating, and high-pressure fusion granulation technology. Nanoparticle liposome encapsulation, esterification modification, and pH-responsive enteric coating improve the stability and bioavailability of the components, solving the problems of poor water solubility, low absorption, and easy degradation of natural active ingredients. The granule has clear efficacy, high safety, and stable process, and can be used as a medical food for adjuvant therapy and nutritional support during the recovery period of liver cancer.

The application discloses a high-activity UGT1A1 enzyme based on tree shrew and a feed composition for enhancing alcohol metabolism. The catalytic efficiency of the recombinant tree shrew UGT1A1 enzyme on ethanol is significantly higher than that of human isozyme. The core of the application is to provide a complex feed system containing the enzyme, which solves the key bottleneck of poor stability and low delivery efficiency of exogenous enzymes in application through the synergistic effect of enzyme stabilizers, cell penetration enhancers, enteric coatings and coenzyme supply agents. Animal experiments show that the composition can safely and effectively accelerate in vivo alcohol elimination and reduce blood ethanol concentration, and can be used for developing alcoholism products, acute alcoholism treatment drugs and alcoholic liver disease prevention preparations.

The invention belongs to the technical field of traditional Chinese medicine preparations, and particularly relates to a traditional Chinese medicine preparation for treating pleural effusion and peritoneal effusion and a preparation method thereof.The traditional Chinese medicine preparation is prepared from, by weight, 10-50 parts of traditional Chinese medicine extract, 30-70 parts of filler, 5-20 parts of enteric coating material, 5-15 parts of HPMC, 0.5-2 parts of triethyl citrate and 0.25-1.5 parts of magnesium stearate; poria cocos, polyporus umbellatus, rhizoma alismatis, astragalus membranaceus, curcuma zedoary, cassia twig, oldenlandia diffusa, sculellaria barbata, semen coicis and traditional Chinese medicine extracts are used as cores, the stability of volatile drugs is improved through an inclusion technology, and the volatile drugs are entrapped in a pH intelligent response type enteric coating material composed of aromatic ring-containing vinyl monomers, ethyl acrylate, DMAEMA and MAA. The traditional Chinese medicine preparation has the synergistic effect of efficiently inducing diuresis, activating blood circulation and eliminating tumors and enteric-coated long-acting directional delivery, and is suitable for patients with pleural effusion and peritoneal effusion, especially malignant effusion.

The invention provides a bromocriptine mesylate enteric-coated tablet and a preparation method thereof. Specifically, the bromocriptine mesylate enteric-coated tablet comprises a tablet core and an enteric coating layer wrapping the tablet core. The enteric-coated tablet disclosed by the invention is simple in process, good in stability and small in gastrointestinal side effect, the bioavailability of the enteric-coated tablet is more than two times that of a common tablet sold in the market, the dosage is expected to be reduced, the side effect is further reduced, and the enteric-coated tablet has excellent clinical value.

Modified release formulations, such as solid oral dosage forms comprising a core composition comprising Compound (I) and / or a pharmaceutically acceptable salt thereof; a sub-coating layer coating the core composition, said sub-coating layer comprising a polyvinyl alcohol and / or a hydroxypropyl methyl cellulose; and an enteric coating layer encapsulating the sub-coating layer and the core composition, said enteric coating layer comprising at least one polymer selected from an acrylic / methacrylic / ethacrylic acid homopolymer and copolymers thereof, a cellulose derivative, and a polyvinylpyrrolidone, and methods of administration of a Bruton's tyrosine kinase (BTK) inhibitor using said formulations.

The invention discloses a tacrolimus-containing pellet pharmaceutical composition, the pharmaceutical composition is composed of an enteric pellet and a sustained-release pellet, the enteric pellet comprises 0.5-5% of tacrolimus, 10-80% of a filler, 2-10% of a disintegrating agent, 1-5% of an adhesive, 0.5-2% of a flow aid, 0.5-1% of a lubricant, and 5-13% of an enteric coating material; the sustained-release pellet comprises 0.5 to 2% of tacrolimus, 10 to 80% of a filling agent, 2 to 10% of a disintegrating agent, 1 to 5% of an adhesive, 0.1 to 1% of a flow aid, 0.1 to 1% of a lubricant, 5 to 15% of a sustained-release coating material and 0.1 to 0.5% of a plasticizer. The pellet pharmaceutical composition containing tacrolimus disclosed by the invention can maintain longer blood concentration and longer action time, so that the medicine taking frequency is reduced, the compliance of a patient is improved, the toxic and side effects are reduced, and the effectiveness and safety of medicine use are further ensured.

This utility model relates to the technical field of coating devices, specifically a coating device for the enteric coating layer of bisacodyl enteric-coated tablets. It includes a cabinet with a roller inside. A rotating ring is connected to the left side wall of the cabinet, and the left end of the rotating ring is rotatably connected to the inner left side wall of the cabinet via a bearing. In operation, bisacodyl tablets are placed into the roller, the door is closed, and a motor drives the drive wheel, transmission belt, driven wheel, rotating ring, and roller to rotate. Support rollers provide support and improve the stability of the roller's rotation. A peristaltic pump draws and delivers the coating solution to the nozzle of a spray gun. The spray gun is connected to a compressed air pipeline, and the compressed air is used to evenly spray the coating solution onto the surface of the bisacodyl tablets for coating. The rotation of the roller causes the tablets to continuously rotate, ensuring the uniformity of the coating solution spray, thereby effectively coating the surface of the bisacodyl tablets with an enteric coating layer.

A method for manufacturing a tablet, preferably a 3D printable pharmaceutical product (100). The method as described herein comprises repeated steps of: providing a layer of a homogeneous powder formulation (1), the formulation comprising a first excipient (2) and an active pharmaceutical ingredient (3). The tablet comprising a core and an enteric coating. Preferably the core comprises an active pharmaceutical ingredient (API).

The invention discloses a preparation method of a magnesium glycinate enteric-coated sustained-release capsule, and relates to the technical field of preparation of enteric-coated sustained-release capsules, and the preparation method is technically characterized by comprising the following steps: preparing a magnesium glycinate pellet: mixing magnesium glycinate with microcrystalline cellulose, starch and cane sugar to form uniform powder, adding the mixed powder into a centrifugal granulating and coating machine, and carrying out granulation and coating to obtain the magnesium glycinate pellet; taking hydroxypropyl methyl cellulose or a methyl cellulose solution as an adhesive, and performing centrifugal granulation at four stages of nucleation, coalescence, lamination and rolling compaction to obtain magnesium glycinate pellets; the nucleation is that the initial particles attract and are connected with one another due to the formation of a three-phase structure in the wetting process of the adhesive; the coalescence is that parent nuclei are combined to form larger particles due to random collision among the large particles; through a synergistic process of four-stage centrifugal granulation, specific-ratio slow-release coating and HPMCP enteric coating, efficient and accurate controlled release of magnesium glycinate is realized, and the problem of too fast release caused by insufficient weight gain of the slow-release coating is effectively avoided.

A drug delivery device includes an ingestible pill including an enteric coating that covers a patch which defines therein a chamber, the patch being constructed to allow entry of liquid into the chamber. The patch includes at least one raised pouch that protrudes outwardly from the patch and which is in fluid communication with the chamber. The at least one raised pouch includes at least one drug-delivery needle. A gas-generating substance is disposed in the chamber. The gas-generating substance is configured to release gas after the liquid has entered the chamber, the gas being flowable into the at least one raised pouch.

This application provides a pharmaceutical composition comprising: an active ingredient, a filler, a disintegrant, and optionally one or more of a binder, a flow aid, and a lubricant. It also provides an enteric-coated tablet comprising (1) a core containing the aforementioned pharmaceutical composition; (2) an optional insulating layer; and (3) an enteric coating layer. The active ingredient in the enteric-coated tablet is not released in the stomach but is released in the intestines, preventing the active ingredient in the composition from degrading in the acidic environment of the stomach.

In some embodiments, the disclosed technology includes a surgical adjunct 604 comprising: a polyurethane foam, the volume ratio of the polyurethane foam to the total volume of the surgical adjunct 604 being in the range of from about 0.125 to about 0.325; and at least one hydrophobic additive comprising at least one ceramic nanoparticle, at least one fatty acid, at least one ionic liquid, at least one long chain surfactant, at least one enteric coating, at least one photocurable resin, or a combination thereof.

The invention discloses a full-peptide compound preparation for nourishing heart and cerebral vessels. The full-peptide compound preparation comprises a core layer and an outer coating, the core layer contains Yang tonifying and Yang recuperating decoction source small molecule peptide and modern bioactive components, and the outer layer is a moisture-proof, slow-release or enteric coating. The preparation is stable in structure and good in absorption and utilization effect, is suitable for the fields of functional foods, health foods, special diets and the like, and has a good industrialization prospect.

The invention discloses a formula and a preparation method of a stomach-invigorating parasite-expelling tablet for livestock. The parasite expelling tablet is formed by compounding and tabletting parasite expelling core enteric particles A and stomach invigorating and relieving quick-release particles B. The particles A contain praziquantel and levamisole or salts thereof, and are coated with enteric materials, so that the parasite expelling activity is limited in gastric segment release and is quickly released in intestinal segment; the particles B contain a cortex meliae extract, a fructus quisqualis extract, pericarpium citri reticulatae, fried malt and fructus crataegi, are compounded with mucous membrane protection or adsorption stimulation components such as sodium alginate / pectin / montmorillonite and the like, and are subjected to post-treatment adsorption through essence, so that the taste covering stability is improved. The preparation method comprises the following steps: plant extraction, wet granulation in two ways, enteric coating of particles A, essence post-treatment of particles B, and compounding, lubricating and tabletting. According to the scheme, the insect expelling effect is guaranteed, gastrointestinal stimulation is reduced, the voluntary ingestion rate and administration compliance are improved, and the composition is suitable for dogs, cats and livestock to expel insects by oral administration.

The invention provides a pH response type metal-polyphenol oral nano-composite as well as a preparation method and application thereof, and belongs to the field of nano-composites and drug delivery systems applied to treatment of inflammatory bowel diseases. According to the invention, zinc chloride and gallic acid are used as raw materials, Zn-GA nanoparticles are formed through a chelation reaction, and the Zn-GA-ES100 nano-composite is formed by wrapping the Zn-GA-ES100 nano-composite with an enteric coating layer ES100. The Zn-GA and ES100 nano-composite can be used for treating IBD, solves the problem that the treatment effect is not ideal due to a single regulation mechanism and insufficient intestinal targeting, can be enriched to an IBD inflammatory microenvironment in a targeted manner, specifically releases metal Zn < 2 + > with an intestinal flora regulating function and natural polyphenol GA with an intestinal barrier repairing function, intervenes intestinal microecology, and can be used for treating IBD. The development and evolution of IBD inflammation are comprehensively blocked, and efficient treatment on IBD is realized.

The present application relates to the technical field of pharmaceutical compositions, and provides a composition for improving immune function, a preparation and a preparation method and application thereof, comprising: 25-40% of chlorogenic acid, 5-12% of luteolin, 10-20% of isochlorogenic acid A, 3-8% of caffeic acid, 0.5-1% of a targeting ligand, 2-5% of a microecological component, and 5-8% of a nano-carrier, and application of the composition in preparation of medicines, health products and functional foods for improving immune function, and a preparation method of the above-mentioned medicine preparation, comprising the following steps: preparing a core particle; coating the core particle with a sustained-release enteric coating to obtain a microcapsule particle; filling the microcapsule particle into a capsule shell to obtain an enteric capsule; coating the enteric capsule with a stomach-dissolving coating liquid to obtain a capsule preparation; and achieving the effect of improving the whole gastrointestinal immune function by rapidly targeting anti-inflammation in the stomach and continuously targeting regulation in the intestinal tract, and greatly improving the action efficiency and immune regulation effect of the preparation.

The invention discloses a cistanche probiotic fermented product and a preparation method thereof, and relates to the technical field of probiotic fermented products, the fermented product comprises an external quick-release layer and an internal enteric slow-release layer, the external quick-release layer comprises a cistanche fermented product, a cistanche extract, a plant function extract and a quick-release auxiliary material, and the internal enteric slow-release layer comprises an internal enteric slow-release layer. The internal enteric slow-release layer comprises special probiotics, soluble dietary fibers and a slow-release matrix which are embedded by double-layer microcapsules, and an enteric coating is applied to the outer surfaces of the double-layer microcapsules and / or the tablet core assembled by the double-layer microcapsules; wherein the cistanche deserticola fermentation product is obtained by taking a cistanche deserticola raw material as a matrix and carrying out compound fermentation on at least one lactic acid bacterium and at least one butyric acid producing bacterium, the fermentation product disclosed by the invention adopts an external quick release layer-internal slow enteric coating core-wrapped structure, a progressive curve of gastric segment quick release-intestinal segment start is formed, and interlayer interference and advanced leakage are avoided.

The present invention relates to a unique coating comprising a hydrophobic matrix of fatty acids and a water-soluble weak organic acid. During acidic conditions (e.g., pH≤3), the weak organic acid is protonated and is almost insoluble or slowly solubilized, while at neutral to alkaline pH (e.g., pH 6 or higher) it is deprotonated and more easily solubilized, allowing for the release of the active ingredient. All of the materials in the coating are soluble in organic solvents and, preferably, alcohols. In at least one embodiment, the coating is used as an enteric coating. In at least one embodiment, the coating is evenly dispersed without the inclusion of a plasticizer, emulsifier, or emulsifying agent.

The invention discloses an icariin enteric-coated sustained-release pellet and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine preparations, and the pellet sequentially comprises a drug-containing pellet core, a sustained-release coating layer and an enteric coating layer from inside to outside. The pellet core contains icariin, microcrystalline cellulose, an adhesive, a disintegrating agent and an antioxidant; the sustained-release coating layer takes ethyl cellulose as a sustained-release material; the enteric coating layer takes acrylic resin and sodium alginate as dual pH response materials, the 2-hour release rate of the pellet in a hydrochloric acid solution with the pH value of 1.0 is less than 10%, the pellet presents near-zero-order release kinetics in a buffer solution with the pH value of 6.8 within 12 hours, the problems that icariin is degraded in gastric acid, the bioavailability is low and the half-life period is short are solved, the icariin can be administrated twice a day, and the bioavailability is high. The traditional Chinese medicine composition is used for treating kidney-yang deficiency type impotence, premature ejaculation and infertility.

The application belongs to the technical field of traditional Chinese medicine preparation, and discloses a traditional Chinese medicine pellet preparation based on intestinal flora regulation and a taste masking process thereof. The traditional Chinese medicine pellet preparation is realized intestinal positioning release through specific sequence process, isolation layer and enteric coating in cooperation with taste masking. After the pellet is released in the intestinal positioning release, the contained medicinal material components can regulate intestinal flora in cooperation, and the intestinal flora can also transform the medicinal material components so that the medicinal material components are more easily absorbed. The effect of the pellet preparation of the application on regulating intestinal flora is better than that of ordinary preparation, which indicates that intestinal positioning release promotes drug efficacy. The application realizes complete taste masking, enhanced drug efficacy and high patient compliance through double cooperation.

The invention provides a coenzyme Q10 enteric capsule as well as a preparation method and application thereof, and belongs to the technical field of preparation of pharmaceutical preparations. The coenzyme Q10 enteric capsule provided by the invention is prepared from coenzyme Q10, olive oil, carnauba wax, vitamin E and an enteric coating material. The coenzyme Q10 enteric capsule provided by the invention can effectively protect the coenzyme Q10 from being damaged by gastric acid and can be quickly released in intestinal tracts, so that the bioavailability of the medicine is remarkably improved. In-vitro dissolution experiments show that the release rate of the coenzyme Q10 enteric capsule in simulated gastric juice within 2 hours is lower than 10%, and the release rate of the coenzyme Q10 enteric capsule in simulated intestinal juice within 30 minutes is higher than 80%. Cell experiments prove that the coenzyme Q10 enteric capsule provided by the invention is good in biocompatibility and free of remarkable cytotoxicity. Animal pharmacokinetic experiments show that the plasma peak concentration and bioavailability of the coenzyme Q10 enteric capsule provided by the invention are obviously higher than those of commercially available soft capsules and tablets.

The invention relates to the technical field of feed preparation, and particularly discloses a biological feed for relieving stress of piglets after weaning and a preparation method thereof.The biological feed comprises, by weight, a basic material and an active material, the active material comprises 4-6 parts of composite mineral particles and 8-12 parts of enteric flavone particles, the composite mineral particles take bentonite as a framework, sodium bicarbonate and an inorganic ion carrier are doped into the inner layer, and an enteric coating is arranged on the outer layer; the enteric flavone particles comprise flavonoid compounds, and enteric coatings are arranged on the outer layers of the enteric flavone particles. The improved composite mineral particles and enteric flavone particles are introduced, buffer salt in the inner layers of the composite mineral particles can locally adjust pH and osmotic pressure in small intestines, the intestinal epithelium electrolyte environment can be stabilized, intestinal acidification caused by weaning stress is relieved, the intestinal flora steady state recovery speed can be remarkably increased, and the diarrhea rate can be remarkably reduced.

The present application relates generally to dosage forms (e.g., oral dosage forms) and pharmaceutical compositions comprising a pharmaceutically active agent comprising telotristat or a pharmaceutically acceptable salt, solvate, or hydrate thereof; an enteric coating; and optionally one or more pharmaceutically acceptable excipients; and to methods of using the dosage forms and pharmaceutical compositions, and methods of making the dosage forms and pharmaceutical compositions.

The invention discloses functional feed for protecting liver and intestines of mandarin fish and a preparation method of the functional feed, and belongs to the technical field of feed. The functional feed for protecting the liver and the intestine of the mandarin fish comprises the following components: an intestine and liver protecting compound, an enteric coating material, an adsorbent, an anti-sticking agent, a protein source, a fat source, carbohydrate, compound vitamins and compound minerals. The preparation method comprises the following steps: firstly, preparing a coating solution, putting an intestine and liver protecting compound into a fluidized bed, spraying the coating solution at the bottom, curing, adding an adsorbent, and mixing to obtain a coated compound; then mixing a protein source, a fat source and carbohydrate to obtain a basic nutrient; and finally, mixing the coated compound, the basic nutrient mixture, the compound vitamins and the compound minerals, extruding and granulating, spraying an anti-sticking agent, and drying to obtain the feed. The functional feed for protecting liver and intestine of mandarin fish provided by the invention can inhibit fatty acid synthase in liver, reduce liver lipid deposition of mandarin fish, restore the liver-body ratio, improve the feed conversion rate and enhance the growth performance of mandarin fish.

A drug delivery device includes an ingestible pill including an enteric coating that covers a patch which defines therein a chamber, the patch being constructed to allow entry of liquid into the chamber. The patch includes at least one raised pouch that protrudes outwardly from the patch and which is in fluid communication with the chamber. The at least one raised pouch includes at least one drug-delivery needle. A gas-generating substance is disposed in the chamber. The gas-generating substance is configured to release gas after the liquid has entered the chamber, the gas being flowable into the at least one raised pouch.

The invention provides an oral solid formulation comprising (a) a plurality of controlled release components comprising (i) a core comprising a mixture of levodopa and at least one pharmaceutically acceptable excipient, (ii) a controlled release coating surrounding the core, (iii) a muco-adhesive coating surrounding the controlled release coating and (iv) an enteric coating surrounding the muco-adhesive coating; and (b) one or more immediate release components comprising levodopa.

This invention belongs to the field of pharmaceutical formulation technology, specifically a microcapsule composition for intestinal targeting and its preparation method. This invention overcomes the problems of poor sustained-release effect and low bioavailability of intestinal-targeted drugs in existing technologies. The microcapsule composition includes a drug-loaded core, an isolation layer, and an enteric coating layer. The drug-loaded core is prepared by extrusion and spheronization of an active drug, cross-linked sodium carboxymethyl cellulose, and povidone. The isolation layer is formed by drop-adding the drug-loaded core into an isolation layer solution. The enteric coating layer is obtained by fluidized bed coating, and the microcapsule composition is obtained by soybean oil treatment. The final targeted microcapsules exhibit excellent sphericity, stable release, and low toxicity, making them suitable for long-term treatment of ulcerative colitis.

The present invention relates to a solid dosage form comprising a coating based on natural ingredients, such as naturally occurring esterified and non-esterified polyuronic acids, optionally in combination with a stabilizing lipophilic component, such as a surfactant, and / or other stabilizing components. The present inventors have made a surprising discovery that polysaccharide-based coatings can be stabilized by the inclusion of specific additives and / or additional layers and often imparted gastric tolerance properties. In particular, a coating comprising a polyuronic acid may be stabilized and rendered more robust by comprising a lipophilic component (e.g., a surfactant), an esterified polyuronic acid, and / or by deploying an additional coating layer comprising a stabilizer that affects disintegration and / or dissolution of the polyuronic acid. The coating comprising the polyuronic acid of the present invention can exhibit delayed disintegration at gastric pH while remaining readily disintegrable at higher pH. Thus, the coatings of the invention provide, inter alia, promising candidates for enteric coatings.